Tue, December 14, 2010
Mon, December 13, 2010
Sun, December 12, 2010
Fri, December 10, 2010
Thu, December 9, 2010
Wed, December 8, 2010
Tue, December 7, 2010
Mon, December 6, 2010
Fri, December 3, 2010
Thu, December 2, 2010
Wed, December 1, 2010
Tue, November 30, 2010
[ Tue, Nov 30th 2010 ]: Market Wire
2005 Certification
Mon, November 29, 2010
Thu, November 25, 2010
Wed, November 24, 2010
Tue, November 23, 2010
Mon, November 22, 2010
Sat, November 20, 2010
Fri, November 19, 2010

Teva to Present at the NASDAQ OMX 25th Investor Program


  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. ent-at-the-nasdaq-omx-25th-investor-program.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

JERUSALEM--([ BUSINESS WIRE ])--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the NASDAQ OMX 25th Investor Program in London with Eyal Desheh, Chief Financial Officer, presenting on Tuesday, December 7, 2010.

What: Teva Presentation at the NASDAQ OMX 25th Investor Program, London

Who: Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries

When: Tuesday, December 7, 2010 at 9:00 AM (local time) / 4:00 AM ET

Where:[ www.tevapharm.com/financial/ ] or [ http://investor.shareholder.com/nasdaq/london_Dec2010/eventdetail.cfm?eventid=88975 ]

How: Live over the Internet -- log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 40,000 people around the world and reached $13.9 billion in net sales in 2009.


Publication Contributing Sources